| NCT ID | NCT06677424 |
| Status | Recruiting |
| Phase | — |
| Sponsor | HealthTech Connex Inc. |
| Condition | Healthy Controls |
| Study Type | INTERVENTIONAL |
| Enrollment | 810 participants |
| Start Date | 2024-08-05 |
| Primary Completion | 2025-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 810 participants in total. It began in 2024-08-05 with a primary completion date of 2025-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to understand how the brain responds to sounds and words, and how this response varies between individuals. The purpose if this study is to develop data set comparing the results from one individual with those from other members (a reference interval database of NeuroCatch® Platform 2) and to quantify the expected distribution across sex and age. NeuroCatch® Platform 2, is a medical device approved by Health Canada. The plan is to enroll 810 participants, the study includes screening for eligibility and one brain scan. The study is conducted at the Centre for Neurology Studies in Surrey, BC or at its satellite sites ( if required).
Eligibility Criteria
INCLUSION CRITERIA 1. Any sex, at least 6 years of age or older 2. Able to understand the informed consent/assent form (in English), study procedures and willing to participate in study; participants under 19 must also have a parent/guardian who is able to understand and provide informed consent on their behalf. 3. Able to remain seated and focused for 7 minutes 4. In good health with no history of clinically relevant neurological illness or injury EXCLUSION CRITERIA 1. Requires the use of hearing aids or a cochlear implant, diagnosed with tinnitus that is currently active, or has temporary damage to hearing (e.g., punctured ear drum). Or unable to detect a 740Hz tone played at 85dB in both ears. 2. Implanted pacemaker or other electrical stimulator(s) 3. Metal or plastic implants in the skull, excluding dental/facial implants. 4. Not native-level in English 5. Previous exposure to the NeuroCatch® Platform 2 audio sequences in the last 3 months 6. History of clinically relevant neurological disorders or injury (e.g., epilepsy, Parkinson's disease, traumatic brain injury, etc.) 7. History of chronic pain or chronic headache disorders (e.g. migraine, tension headaches, fibromyalgia, etc.) 8. Currently diagnosed with any sleeping disorders (e.g. sleep apnea, hypersomnia, insomnia, parasomnia, etc.) 9. Diagnosed with any memory disorders. 10. History of clinically relevant major psychiatric disorders (e.g., schizophrenia, bipolar disorder, etc.) 11. History of alcohol or substance misuse that, in the opinion of the Investigator, may impact brain function 12. Use of medications that affect brain function (e.g., antiepileptic drugs, antipsychotics, stimulants, etc.) 13. Serious medical conditions affecting brain functions (e.g., stroke, brain tumor, neurodegenerative diseases, etc.) 14. Undergoing chemotherapy or any form of intensive long-term therapy that, in the opinion of the Investigator, may impact brain function. 15. Unhealthy scalp (e.g., apparent open wounds and/or bruised or weakened skin) 16. Allergy to EEG gel
Contact & Investigator
Jan Venter, MD
PRINCIPAL INVESTIGATOR
Centre for Neurology Studies
Frequently Asked Questions
Who can join the NCT06677424 clinical trial?
This trial is open to participants of all sexes, aged 6 Years or older, studying Healthy Controls. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06677424 currently recruiting?
Yes, NCT06677424 is actively recruiting participants. Contact the research team at cnsneurostudies@gmail.com for enrollment information.
Where is the NCT06677424 trial being conducted?
This trial is being conducted at Surrey, Canada.
Who is sponsoring the NCT06677424 clinical trial?
NCT06677424 is sponsored by HealthTech Connex Inc.. The principal investigator is Jan Venter, MD at Centre for Neurology Studies. The trial plans to enroll 810 participants.